Delcath Systems Inc Dossier - Source-backed chat

Delcath Systems Inc

DCTHNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.68

Intrinsic Value $7.16median of 5 methods · middle span $5-$95based on filings through 30 Jun 2026

Market Price $15.41Price as of 1 Oct 2026

Significantly overvaluedIntrinsic value is 54% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (-54%)

Data confidence Sign in to view data confidence

Market Cap $534.7M

Enterprise Value $487.2M

Shares Outstanding 39.6M diluted

Moat Rating None

Next Earnings Date3 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Delcath Systems, Inc. (Nasdaq: DCTH) is transitioning from a clinical-stage interventional oncology company to a high-growth commercial entity, driven by the successful rollout of its FDA-approved HEPZATO KIT in the United States and CHEMOSAT in Europe. With record Q1 2026 revenues of $25.0 million (up 26.3% YoY) and full-year 2026 revenue guidance of at least $100 million, the company is demonstrating strong commercial execution. The publication of the CHOPIN Phase 2 trial results in The Lancet Oncology is actively driving physician adoption and guideline inclusion, establishing a solid foundation for long-term growth. Backed by a robust cash position of $89.3 million and zero debt, Delcath is well-positioned to fund its commercial expansion and pipeline trials in colorectal and breast cancers.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$17.00

Mean target$21.55

High · most bullish analyst$29.76

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects potential commercial bottlenecks, including persistent capacity constraints, patient scheduling delays, or seasonal slowdowns in Q3 and Q4. If site activations stall below 35 or new patient starts decline due to competitive clinical trial activities, revenue may fall short of the $100 million guidance. Additionally, slower-than-expected clinical trial enrollment in the colorectal or breast cancer programs could delay pipeline expansion and pressure the stock.

Base CaseCentral scenario

The base case assumes Delcath successfully executes its commercial strategy, expanding its active treatment centers to 40 by the end of 2026 and achieving its full-year revenue guidance of at least $100 million. Volume growth for the HEPZATO KIT is expected to remain above 20%, supported by the completed expansion of the U.S. commercial team to nine regions. Clinical trials in colorectal and breast cancers will progress on schedule, maintaining investor confidence and driving steady valuation expansion.

Bull CaseUpside scenario

The bull case for Delcath Systems is driven by the commercial execution and clinical validation of its HEPZATO KIT. Key growth drivers include expanding the number of REMS-certified treatment sites (targeting 37 active centers by year-end 2026 and 40 in Q1 2027) and increasing utilization. Clinical validation is strongly supported by the publication of the CHOPIN Phase 2 trial results in The Lancet Oncology, which demonstrated that combining HEPZATO with immunotherapy (ipilimumab and nivolumab) improved tumor response rates from 40% to 76% and significantly improved progression-free survival in metastatic uveal melanoma. Additionally, the company is expanding its clinical pipeline with active Phase 2 trials in liver-dominant metastatic breast cancer (PHP-MBC-202) and metastatic colorectal cancer, which represent substantial long-term market expansion opportunities.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial momentum with Q1 2026 revenue growing 26.3% YoY to $25.0 million, driven by HEPZATO KIT sales of $23.3 million.
Robust balance sheet with $89.3 million in cash and investments and zero debt as of March 31, 2026, providing a runway of at least 12 months.
High-impact clinical validation from the CHOPIN trial published in The Lancet Oncology, which is actively influencing treatment patterns and driving guideline inclusion.
Clear expansion path with ongoing Phase 2 trials in liver-dominant metastatic colorectal cancer and metastatic breast cancer.

Key Investment Risks

Capacity constraints and patient scheduling delays at active treatment centers, which could limit volume growth.
Pronounced seasonal trends in patient starts, particularly during the summer months, which can create quarterly revenue volatility.
High dependence on a single core technology platform (Hepatic Delivery System) for both HEPZATO and CHEMOSAT.
Rising operating expenses (R&D and SG&A) as the company expands its commercial footprint and clinical pipeline, delaying GAAP net profitability.

Thesis Invalidation Triggers

Full-year 2026 revenue falling significantly below the guided $100 million threshold.
A material decline in the rate of new patient starts per site per month below 0.5.
Failure to activate targeted clinical trial sites for the colorectal (26 sites) or breast cancer (15 sites) programs by the end of 2026.
Safety signals or regulatory actions that restrict the HEPZATO KIT Risk Evaluation and Mitigation Strategy (REMS) program.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.